Goserelin

CHEMBL1201247 Phase 4 معتمد Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1269.4 g/mol

LogP

-1.5

Phase

4

A synthetic gonadotropin-releasing hormone agonist used to reduce testosterone or estrogen levels as a treatment for prostate cancer, breast cancer, endometriosis, and uterine fibroids by initially stimulating and then suppressing sex hormone production. Regular monthly or three-monthly subcutaneous implants maintain hormone suppression. It is also used to protect ovarian function during chemotherapy.

الوزن الجزيئي

1269,4000 g/mol

LogP

-1,50

TPSA

496,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Non-Small Cell Lung Cancer Osteoporosis Schizophrenia Melanoma Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O

InChI

InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1

Molecular Formula

C59H84N18O14

HBD / HBA

17 / 16

الروابط القابلة للدوران

32

الذرات الثقيلة

91

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A synthetic gonadotropin-releasing hormone agonist used to reduce testosterone or estrogen levels as a treatment for prostate cancer, breast cancer, endometriosis, and uterine fibroids by initially stimulating and then suppressing sex hormone production. Regular monthly or three-monthly subcutaneous implants maintain hormone suppression. It is also used to protect ovarian function during chemotherapy.

Yes, Goserelin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201247. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5311128. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Goserelin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C59H84N18O14
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.